CELLDEX THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.01 USD | +0.76% |
|
-3.54% | -16.77% |
Financials (USD)
| Sales 2024 * | 2.71M | Sales 2025 * | 2.66M | Capitalization | 2.18B |
|---|---|---|---|---|---|
| Net income 2024 * | -153M | Net income 2025 * | -196M | EV / Sales 2024 * | 802 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 819 x |
| P/E ratio 2024 * |
-14.3
x | P/E ratio 2025 * |
-11.5
x | Employees | 160 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.67% |
More Fundamentals
* Assessed data
More news
Latest transcript on Celldex Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +0.76% | ||
| 1 week | -3.54% | ||
| Current month | -0.87% | ||
| 1 month | -22.44% | ||
| 3 months | -33.99% | ||
| 6 months | +4.23% | ||
| Current year | -16.77% |
1 week
32.25
34.58
1 month
32.2543.35
Current year
32.2553.18
1 year
22.1153.18
3 years
19.8557.20
5 years
1.5057.20
10 years
1.50492.30
| Managers | Title | Age | Since |
|---|---|---|---|
Tibor Keler
FOU | Founder | 65 | 82-12-31 |
Anthony Marucci
FOU | Founder | 62 | 82-12-31 |
Sam Martin
DFI | Director of Finance/CFO | 53 | 09-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Herbert Conrad
BRD | Director/Board Member | 91 | 08-02-29 |
Cheryl Cohen
BRD | Director/Board Member | 58 | 22-06-15 |
Harry Penner
BRD | Director/Board Member | 78 | 96-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% | ||
| 0.02% | 9 M€ | +10.33% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 33.01 | +0.76% | 510,550 |
| 24-06-04 | 32.76 | -2.12% | 1,012,487 |
| 24-06-03 | 33.47 | +0.51% | 874,595 |
| 24-05-31 | 33.3 | -0.95% | 490,434 |
| 24-05-30 | 33.62 | -1.75% | 615,222 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotes
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Companyâs bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
33.01
USD
Average target price
69
USD
Spread / Average Target
+109.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.77% | 2.18B | |
| +55.70% | 59.34B | |
| +41.08% | 40.24B | |
| -5.39% | 39.88B | |
| -5.56% | 28.55B | |
| +16.46% | 27.26B | |
| -20.56% | 19.23B | |
| +33.03% | 12.61B | |
| +25.85% | 12.28B | |
| +2.72% | 12.49B |
- Stock Market
- Equities
- CLDX Stock
